Atsuhiro Maeda, Kazuhiko Tsuruya, Maki Maeda, Masatora Yamasaki, Aki Nakashima, Yui Nakashima, Saori Date, Toshiro Maeda, Masafumi Kamijyou, Takuya Kubara, Waka Hayashi, Takanari Kitazono
INTRODUCTION: High-dose erythropoietin (EPO) administration to hemodialysis (HD) patients with EPO hyporesponsiveness, due to iron deficiency, hyperparathyroidism, malnutrition, inflammation, and inadequate HD, results in increased risk of mortality and cardiovascular events. We investigated the relationship of the EPO dose requirement with 4-, 5-, and 6-hour HD treatment times. MATERIALS AND METHODS: This cross-sectional study enrolled 300 HD patients, including those on 4-hour HD (n = 78), 5-hour HD (n = 106), and 6-hour HD (n = 116)...
October 2019: Clinical Nephrology